Payment overview · 2025
General Payments
$2,407.57
135 reported records · 28 companies
Healthcare provider profile · identity verified
Matthew Daniel Prine, MD
Allopathic & Osteopathic Physicians|Family Medicine · RAYVILLE, LA · NPI 1558650861
Verified facts
What the public records show
CMS Open Payments records show Matthew Daniel Prine, MD received $2,407.57 in general payments during 2025 across 135 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Auvelity by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulance by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $301.16 | 12.5% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $301.01 | 12.5% | 22 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $220.78 | 9.2% | 16 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $202.59 | 8.4% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $179.38 | 7.5% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $157.64 | 6.5% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $146.79 | 6.1% | 7 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $135.56 | 5.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $101.87 | 4.2% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $90.22 | 3.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.52 | 3.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.13 | 3.0% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.42 | 1.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $39.26 | 1.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.36 | 1.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.71 | 1.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.81 | 1.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $35.19 | 1.5% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.44 | 1.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.02 | 1.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.64 | 0.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.47 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.01 | 0.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.56 | 0.8% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $19.06 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.38 | 0.7% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $14.39 | 0.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.20 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,407.57 | 135 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $220.78 | 16 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $192.15 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $187.40 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $168.43 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $164.50 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $163.29 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $157.64 | 9 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $135.56 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $107.86 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $106.58 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.87 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $101.87 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $91.64 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $90.53 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $90.22 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.04 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $80.60 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.52 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $74.07 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $72.13 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.41 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.81 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $23.30 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $10.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 267 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 214 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 59 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
214 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
267 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
104 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
175 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
267 | 36 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 688 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 605 | 123 |
| Gabapentin | Gabapentin | 552 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 532 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 446 | 77 |
| Losartan Potassium | Losartan Potassium | 441 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 376 | 75 |
| Metformin Hcl | Metformin Hcl | 340 | 68 |
| Potassium Chloride | Potassium Chloride | 331 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 326 | 67 |
| Furosemide | Furosemide | 325 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 319 | 88 |
| Trazodone Hcl | Trazodone Hcl | 311 | 56 |
| Lisinopril | Lisinopril | 301 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 61 |
| Meloxicam | Meloxicam | 275 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 269 | 55 |
| Eliquis | Apixaban | 267 | 36 |
| Montelukast Sodium | Montelukast Sodium | 267 | 65 |
| Omeprazole | Omeprazole | 254 | 51 |
| Methylprednisolone | Methylprednisolone | 245 | 181 |
| Fluticasone Propionate | Fluticasone Propionate | 235 | 85 |
| Azithromycin | Azithromycin | 228 | 170 |
| Farxiga | Dapagliflozin Propanediol | 214 | 27 |
| Mounjaro | Tirzepatide | 175 | 27 |
| Simvastatin | Simvastatin | 172 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 44 |
| Carvedilol | Carvedilol | 151 | 28 |
| Clonidine Hcl | Clonidine Hcl | 146 | 26 |
| Donepezil Hcl | Donepezil Hcl | 143 | 27 |
| Naproxen | Naproxen | 128 | 65 |
| Amitriptyline Hcl | Amitriptyline Hcl | 127 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 41 |
| Clonazepam | Clonazepam | 121 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 119 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 26 |
| Tramadol Hcl | Tramadol Hcl | 113 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 107 | 75 |
| Pregabalin | Pregabalin | 106 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 18 |
| Xarelto | Rivaroxaban | 104 | 16 |
| Ozempic | Semaglutide | 103 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 102 | 26 |
| Ondansetron Odt | Ondansetron | 102 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 17 |
| Allopurinol | Allopurinol | 97 | 20 |
| Jardiance | Empagliflozin | 95 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 23 |
| Nifedipine Er | Nifedipine | 95 | 17 |
| Mirtazapine | Mirtazapine | 93 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 17 |
| Memantine Hcl | Memantine Hcl | 90 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 16 |
| Buspirone Hcl | Buspirone Hcl | 84 | 17 |
| Celecoxib | Celecoxib | 84 | 20 |
| Diazepam | Diazepam | 84 | suppressed |
| Linzess | Linaclotide | 83 | 22 |
| Sertraline Hcl | Sertraline Hcl | 81 | 19 |
| Finasteride | Finasteride | 77 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | 56 |
| Ingrezza | Valbenazine Tosylate | 70 | suppressed |
| Alprazolam | Alprazolam | 69 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 23 |
| Ibuprofen | Ibuprofen | 64 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 12 |
| Digoxin | Digoxin | 61 | suppressed |
| Glipizide | Glipizide | 61 | 14 |
| Spironolactone | Spironolactone | 59 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 59 | 13 |
| Rexulti | Brexpiprazole | 58 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 57 | 12 |
| Divalproex Sodium | Divalproex Sodium | 57 | suppressed |
| Levetiracetam | Levetiracetam | 56 | 11 |
| Mupirocin | Mupirocin | 54 | 26 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 53 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 12 |
| Lovastatin | Lovastatin | 49 | 13 |
| Fluconazole | Fluconazole | 48 | 24 |
| Lorazepam | Lorazepam | 48 | suppressed |
| Prednisone | Prednisone | 48 | 28 |
| Colchicine | Colchicine | 47 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Glimepiride | Glimepiride | 47 | 13 |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 44 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 43 | 12 |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Famotidine | Famotidine | 38 | 11 |
| Kerendia | Finerenone | 38 | suppressed |
| Olanzapine | Olanzapine | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 37 | 13 |
| Haloperidol | Haloperidol | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Novolin R | Insulin Regular, Human | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 26 |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Clonidine | Clonidine | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Nystatin | Nystatin | 28 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Abilify Maintena | Aripiprazole | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Ibu | Ibuprofen | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Ergotamine-Caffeine | Ergotamine Tartrate/Caffeine | 18 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 13 |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Insulin Aspart | Insulin Aspart | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rayaldee | Calcifediol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,407.57 · 135 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COBENFY, CREON, Cologuard Collection Kit, DALVANCE, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, IBSRELA, INVEGA SUSTENNA, JARDIANCE, Kerendia, LINZESS, LYBALVI, MYFEMBREE, NURTEC ODT, OTEZLA, Omnipod, Ozempic, QULIPTA, RELISTOR, REPATHA, REXULTI, Rybelsus, Sunosi, TEFLARO, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VERQUVO, VRAYLAR, Veozah, ZAVZPRET | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error